Cargando…
Incidence of chemotherapy-induced amenorrhea associated with epirubicin, docetaxel and navelbine in younger breast cancer patients
BACKGROUND: The rates of chemotherapy-induced amenorrhea (CIA) associated with docetaxel-based regimens reported by previous studies are discordant. For navelbine-based chemotherapies, rates of CIA have seldom been reported. METHODS: Of 170 premenopausal patients recruited between January 2003 and S...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2893114/ https://www.ncbi.nlm.nih.gov/pubmed/20540745 http://dx.doi.org/10.1186/1471-2407-10-281 |
_version_ | 1782183005792501760 |
---|---|
author | Zhou, Wen-Bin Yin, Hong Liu, Xiao-An Zha, Xiao-Ming Chen, Lin Dai, Jun-Cheng Tao, Ai-di Chen, Ling Ma, Jing-Jing Ling, Li-Jun Wang, Shui |
author_facet | Zhou, Wen-Bin Yin, Hong Liu, Xiao-An Zha, Xiao-Ming Chen, Lin Dai, Jun-Cheng Tao, Ai-di Chen, Ling Ma, Jing-Jing Ling, Li-Jun Wang, Shui |
author_sort | Zhou, Wen-Bin |
collection | PubMed |
description | BACKGROUND: The rates of chemotherapy-induced amenorrhea (CIA) associated with docetaxel-based regimens reported by previous studies are discordant. For navelbine-based chemotherapies, rates of CIA have seldom been reported. METHODS: Of 170 premenopausal patients recruited between January 2003 and September 2008, 78 were treated with fluorouracil plus epirubicin and cyclophosphamide (FEC), 66 were treated with docetaxel plus epirubicin (TE), and 26 were treated with navelbine plus epirubicin (NE). Patient follow-up was carried up every 3-4 months during the first year, then every 9-12 months during subsequent years. RESULTS: In univariate analysis, the rates of CIA were 44.87% for the FEC regimen, 30.30% for the TE regimen and 23.08% for the NE regimen (P = 0.068). Significant differences in the rates of CIA were not found between the FEC and TE treatment groups (P > 0.05), but were found between the FEC and NE treatment groups (P < 0.05). Furthermore, no significant differences were found between the TE and NE regimens (P > 0.05). Tamoxifen use was a significant predictor for CIA (P = 0.001), and age was also a significant predictor (P < 0.001). In multivariate analysis, age (P < 0.001), the type of chemotherapy regimens (P = 0.009) and tamoxifen use (P = 0.003) were all significant predictors. CONCLUSIONS: Age and administration of tamoxifen were found to be significant predictive factors of CIA, whereas docetaxel and navelbine based regimens were not associated with higher rates of CIA than epirubicin-based regimen. |
format | Text |
id | pubmed-2893114 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-28931142010-06-29 Incidence of chemotherapy-induced amenorrhea associated with epirubicin, docetaxel and navelbine in younger breast cancer patients Zhou, Wen-Bin Yin, Hong Liu, Xiao-An Zha, Xiao-Ming Chen, Lin Dai, Jun-Cheng Tao, Ai-di Chen, Ling Ma, Jing-Jing Ling, Li-Jun Wang, Shui BMC Cancer Research Article BACKGROUND: The rates of chemotherapy-induced amenorrhea (CIA) associated with docetaxel-based regimens reported by previous studies are discordant. For navelbine-based chemotherapies, rates of CIA have seldom been reported. METHODS: Of 170 premenopausal patients recruited between January 2003 and September 2008, 78 were treated with fluorouracil plus epirubicin and cyclophosphamide (FEC), 66 were treated with docetaxel plus epirubicin (TE), and 26 were treated with navelbine plus epirubicin (NE). Patient follow-up was carried up every 3-4 months during the first year, then every 9-12 months during subsequent years. RESULTS: In univariate analysis, the rates of CIA were 44.87% for the FEC regimen, 30.30% for the TE regimen and 23.08% for the NE regimen (P = 0.068). Significant differences in the rates of CIA were not found between the FEC and TE treatment groups (P > 0.05), but were found between the FEC and NE treatment groups (P < 0.05). Furthermore, no significant differences were found between the TE and NE regimens (P > 0.05). Tamoxifen use was a significant predictor for CIA (P = 0.001), and age was also a significant predictor (P < 0.001). In multivariate analysis, age (P < 0.001), the type of chemotherapy regimens (P = 0.009) and tamoxifen use (P = 0.003) were all significant predictors. CONCLUSIONS: Age and administration of tamoxifen were found to be significant predictive factors of CIA, whereas docetaxel and navelbine based regimens were not associated with higher rates of CIA than epirubicin-based regimen. BioMed Central 2010-06-11 /pmc/articles/PMC2893114/ /pubmed/20540745 http://dx.doi.org/10.1186/1471-2407-10-281 Text en Copyright ©2010 Zhou et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Zhou, Wen-Bin Yin, Hong Liu, Xiao-An Zha, Xiao-Ming Chen, Lin Dai, Jun-Cheng Tao, Ai-di Chen, Ling Ma, Jing-Jing Ling, Li-Jun Wang, Shui Incidence of chemotherapy-induced amenorrhea associated with epirubicin, docetaxel and navelbine in younger breast cancer patients |
title | Incidence of chemotherapy-induced amenorrhea associated with epirubicin, docetaxel and navelbine in younger breast cancer patients |
title_full | Incidence of chemotherapy-induced amenorrhea associated with epirubicin, docetaxel and navelbine in younger breast cancer patients |
title_fullStr | Incidence of chemotherapy-induced amenorrhea associated with epirubicin, docetaxel and navelbine in younger breast cancer patients |
title_full_unstemmed | Incidence of chemotherapy-induced amenorrhea associated with epirubicin, docetaxel and navelbine in younger breast cancer patients |
title_short | Incidence of chemotherapy-induced amenorrhea associated with epirubicin, docetaxel and navelbine in younger breast cancer patients |
title_sort | incidence of chemotherapy-induced amenorrhea associated with epirubicin, docetaxel and navelbine in younger breast cancer patients |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2893114/ https://www.ncbi.nlm.nih.gov/pubmed/20540745 http://dx.doi.org/10.1186/1471-2407-10-281 |
work_keys_str_mv | AT zhouwenbin incidenceofchemotherapyinducedamenorrheaassociatedwithepirubicindocetaxelandnavelbineinyoungerbreastcancerpatients AT yinhong incidenceofchemotherapyinducedamenorrheaassociatedwithepirubicindocetaxelandnavelbineinyoungerbreastcancerpatients AT liuxiaoan incidenceofchemotherapyinducedamenorrheaassociatedwithepirubicindocetaxelandnavelbineinyoungerbreastcancerpatients AT zhaxiaoming incidenceofchemotherapyinducedamenorrheaassociatedwithepirubicindocetaxelandnavelbineinyoungerbreastcancerpatients AT chenlin incidenceofchemotherapyinducedamenorrheaassociatedwithepirubicindocetaxelandnavelbineinyoungerbreastcancerpatients AT daijuncheng incidenceofchemotherapyinducedamenorrheaassociatedwithepirubicindocetaxelandnavelbineinyoungerbreastcancerpatients AT taoaidi incidenceofchemotherapyinducedamenorrheaassociatedwithepirubicindocetaxelandnavelbineinyoungerbreastcancerpatients AT chenling incidenceofchemotherapyinducedamenorrheaassociatedwithepirubicindocetaxelandnavelbineinyoungerbreastcancerpatients AT majingjing incidenceofchemotherapyinducedamenorrheaassociatedwithepirubicindocetaxelandnavelbineinyoungerbreastcancerpatients AT linglijun incidenceofchemotherapyinducedamenorrheaassociatedwithepirubicindocetaxelandnavelbineinyoungerbreastcancerpatients AT wangshui incidenceofchemotherapyinducedamenorrheaassociatedwithepirubicindocetaxelandnavelbineinyoungerbreastcancerpatients |